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ABSTRACT There is a critical need for improved pharmacodynamic markers for use in
human tuberculosis (TB) drug trials. Pharmacodynamic monitoring in TB has convention-
ally used culture or molecular methods to enumerate the burden of Mycobacterium tuber-
culosis organisms in sputum. A recently proposed assay called the rRNA synthesis (RS) ra-
tio measures a fundamentally novel property, how drugs impact ongoing bacterial rRNA
synthesis. Here, we evaluated RS ratio as a potential pharmacodynamic monitoring tool
by testing pretreatment sputa from 38 Ugandan adults with drug-susceptible pulmonary
TB. We quantified the RS ratio in paired pretreatment sputa and evaluated the relation-
ship between the RS ratio and microbiologic and molecular markers of M. tuberculosis bur-
den. We found that the RS ratio was highly repeatable and reproducible in sputum sam-
ples. The RS ratio was independent of M. tuberculosis burden, confirming that it measures
a distinct new property. In contrast, markers of M. tuberculosis burden were strongly asso-
ciated with each other. These results indicate that the RS ratio is repeatable and reproduc-
ible and provides a distinct type of information from markers of M. tuberculosis burden.
IMPORTANCE This study takes a major next step toward practical application of a
novel pharmacodynamic marker that we believe will have transformative implica-
tions for tuberculosis. This article follows our recent report in Nature Communications
that an assay called the rRNA synthesis (RS) ratio indicates the treatment-shortening
of drugs and regimens. Distinct from traditional measures of bacterial burden, the
RS ratio measures a fundamentally novel property, how drugs impact ongoing bacte-
rial rRNA synthesis.
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To achieve the World Health Organization End TB strategic goals, it will be necessary todevelop new, shorter treatment regimens for both drug-susceptible and drug-resistant
tuberculosis (TB) (1, 2). One key challenge for evaluation of new TB treatment regimens is
the limitation of existing pharmacodynamic (PD) markers (3–5). There is an urgent need
for new PD markers that maximize information gained from preclinical animal models and
early-phase human clinical trials. More accurate PD markers would enable selection of the
most efficacious regimens for testing in definitive phase III trials (6–8).
We recently proposed a new marker of TB treatment efficacy called the rRNA synthe-
sis (RS) ratio (9). In Mycobacterium tuberculosis, the three rRNA sequences are transcribed
on a single polycistronic precursor-rRNA (pre-rRNA) sequence with intervening short
spacer sequences called internally transcribed spacer 1 (ITS1) and externally transcribed
spacer 1 (ETS1) (Fig. 1). Since the spacer sequences are rapidly degraded, they serve as a
marker of newly transcribed rRNA (10). The RS ratio estimates ongoing rRNA synthesis in
M. tuberculosis populations by quantifying the relative abundance of ETS1 sequence rela-
tive to 23S rRNA sequence.
The RS ratio is unlike most conventional and investigational PD markers that enumer-
ate the burden of M. tuberculosis, such as sputum smear grade, time to positivity (TTP) in
liquid culture, GeneXpert MTB/RIF (Xpert) threshold cycle (CT) values, and M. tuberculosis
rRNA burden. In contrast, the RS ratio measures the effect of drugs on the physiologic
state of the pathogen. In principle, the RS ratio provides a different type of information
than these existing measures of M. tuberculosis burden. Key insights from in vitro and
murine studies are (i) drugs often affect the RS ratio and CFU burden differently and (ii)
the RS ratio appears to indicate the sterilizing activity of drugs and regimens (9). This
novel molecular approach has yet to be extensively investigated as a marker in humans.
As a preliminary evaluation of the performance of the RS ratio in human sputum, we
evaluated pretreatment sputa from 38 Ugandan adults with drug-susceptible pulmonary
TB. We tested the repeatability and reproducibility of the RS ratio in paired pretreatment
sputa and evaluated the association of the RS ratio with conventional and investigational
PD markers that enumerate M. tuberculosis burden. Our results suggest that the RS ratio
is repeatable and reproducible and provide a distinct new type of information.
RESULTS
Study population characteristics. Evaluation of 102 adults confirmed drug-suscepti-
ble pulmonary TB among 52 participants. After excluding 14 who declined to participate
or were unable to produce additional sputa, 38 participants were included in this study
(see Fig. S1 in the supplemental material). Table 1 provides participant characteristics.
Repeatability and reproducibility of RS ratio in sputum. In the paired pretreat-
ment sputa, the RS ratio was quantifiable in 97% of first sputum samples (SS1) and 92%
of second sputum samples (SS2). When SS1 samples were assayed in triplicate in a single
experiment for assessment of repeatability, the intraclass correlation coefficient (ICC)
was 0.99. When the RS ratio was conducted by two different lab workers using different
instruments at a 12-month interval, interobserver reproducibility was high (ICC, 0.93).
Repeatability and reproducibility results are summarized in Table 2.
When the RS ratio was compared between two paired sputum samples from the
same participant, the ICC was 0.63, indicating good biological reproducibility. The RS
FIG 1 Schematic of ribosomal operon in M. tuberculosis, illustrating rapidly degraded precursor
spacer sequences (ETS1 and ITS1). The RS ratio is based on the abundance of ETS1 sequence relative
to 23S rRNA sequence.
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ratio estimates did not differ systematically between the first and second sputum sam-
ple (mean difference between RS ratios in SS1 and SS2, –0.11 [95% confidence interval
(CI), –0.26 to 0.03]). The variability of the RS ratio between paired sputum samples
(ICC, 0.63) was comparable to the variation observed in paired sputum samples in M.
tuberculosis 16S rRNA (ICC, 0.64) and 23S rRNA (ICC, 0.64).
Association of RS ratio with markers ofM. tuberculosis burden. There was no sig-
nificant relationship between RS ratios quantified in SS1 and M. tuberculosis rRNA burden,
smear grade, TTP, or Xpert CT value (Table 3), reinforcing our understanding that the RS ratio
provides a different type of information than markers of M. tuberculosis burden. Similar
results were observed using RS ratios quantified in SS2 (Table 3). Conversely, with few excep-
tions, M. tuberculosis rRNA burden, smear grade, TTP, and Xpert CT values were significantly
associated, despite the fact that some measurements were made on different sputum
samples.
TABLE 1 Participant characteristicsa
Variable Value
Age in yrs, median (IQR) 34 (26–38)










TTP in days, median (IQR) 6 (4–9)
Xpert CT cycles, median (IQR) 18.2 (16.3–20.0)
16S burden, median (IQR)b
SS1 6.0 (4.9–7.6)
SS2 5.8 (4.8–7.3)
23S burden, median (IQR)b
SS1 5.4 (4.1–7.3)
SS2 5.2 (3.9–6.7)
RS ratio, median (IQR)b
SS1 3.3 (3.0–3.5)
SS2 3.3 (3.2–3.6)
aIQR, interquartile range; CT, cycle threshold; TTP, time to culture positivity.
blog10-transformed.
TABLE 2 Repeatability and reproducibility of the RS ratio in sputum
Measure Sample Basis for assessment
Intraclass correlation
coefficient














aAgreement among three replicate RS ratio results within a single experiment.
bAgreement between RS ratio results in the same samples conducted by two different lab workers using
different instruments at a 12-month interval.
cAgreement between RS ratio results in two separate sputum samples collected within an hour of each other.
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Association of clinical and demographic factors with the RS ratio and markers
of M. tuberculosis burden. In general, there was no significant relationship between
clinical and demographic factors, including sex, HIV status, and smoking, and the RS ra-
tio or markers of M. tuberculosis burden. The only exception was for the relationship
between Xpert CT values and sex, which had a P value of 0.03 (Table S1). After adjust-
ment for multiple comparisons, this association was nonsignificant.
DISCUSSION
Using sputa from Ugandan adults with untreated TB, we evaluated the RS ratio in
pretreatment sputa and compared the RS ratio with other conventional and investiga-
tional markers. We found that the RS ratio was highly repeatable in technical replicates
and had high interobserver reproducibility. The sputum-to-sputum biological variabili-
ty in the RS ratio approximated the variability observed in M. tuberculosis 16S and 23S
rRNA burden. Comparison of the RS ratio with sputum smear, TTP, Xpert CT values and
M. tuberculosis rRNA burden indicated that the RS ratio measures a distinct property
that is independent of bacterial burden.
An important precursor to establishing a novel PD marker is understanding techni-
cal and biological variability of the assay (11–13). The sputum RS ratio demonstrated
high technical consistency with high repeatability and interobserver reproducibility,
consistent with the previously described performance of droplet digital PCR (ddPCR) in
clinical samples (14, 15).
As anticipated, the biological variability exceeded the technical variability. The
baseline sample is particularly important because clinical trials typically evaluate how
changes in PD marker over time relative to baseline values relate to disease outcomes.
Therefore, evaluating the repeatability and reproducibility of the RS ratio in paired
baseline sputum samples helps us understand the source of variability. We suspect
that the sources of biological variability differ between the RS ratio and markers that
enumerate M. tuberculosis burden. Generally, production of greater sputum volume is
associated with higher M. tuberculosis burden and correspondingly shorter TTP, lower
Xpert values, and higher M. tuberculosis rRNA burden (16–18). The volume of sputum
varies based on time of collection, participant effort to expectorate, and severity of
TABLE 3 Association between the RS ratio in SS1 and SS2 and markers ofM. tuberculosis burdena,d
Markers RS ratiob 16S rRNA burdenb 23S rRNA burdenb Smear grade TTP in liquid culture Xpert CT values
SS1




























TTP in liquid culture r = 0.62
(P, 0.01)
Markers RS ratioc 16S rRNA burdenc 23S rRNA burdenc Smear grade TTP in liquid culture Xpert CT values
SS2
























aSpearman correlation coefficients (r ) with P values (P) are provided. RS ratio and rRNA burden measurements were log10-transformed. CT, cycle threshold; TTP, time to
culture positivity.
bUsing RS ratio, 16S and 23S rRNA from SS1.
cUsing RS ratio, 16S and 23S rRNA from SS2.
dSputum grade was converted to an ordinal scale with negative, positive 11, positive 21, and positive 31 corresponding to 0, 1, 2, and 3, respectively.
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lung disease (16). In contrast, the RS ratio is designed to be “self-normalizing” to bacte-
rial burden because both the pre-rRNA numerator and the 23S rRNA denominator scale
with change in M. tuberculosis burden. For the RS ratio, it is likely that sputum-to-spu-
tum variation indicates biological variability in the M. tuberculosis populations present
in samples originating from different regions of the lung (19, 20).
Consistent with our hypothesis that the RS ratio is not a marker of M. tuberculosis
burden, we did not observe an association between this novel marker and conven-
tional or investigational markers that enumerate M. tuberculosis burden. This is similar
to findings from our in vitro and murine studies (9). Our findings suggest that the RS ra-
tio is a feasible tool for evaluating human sputa that may complement markers of M.
tuberculosis burden, providing novel insight into treatment response.
This study has several limitations. First, although our goal is a PD marker that can
be used to monitor treatment effectiveness, here, we studied only pretreatment sam-
ples. Nevertheless, evaluation of technical and biological variability in pretreatment
samples is an important preliminary step required for interpretation of longitudinal
data. Second, by necessity, we used different sputum samples to evaluate different
markers. For example, smear status and TTP were quantified in one sample, Xpert was
quantified in another, and RS ratio and M. tuberculosis rRNA burden were quantified in
separate paired samples. Nonetheless, all of the markers that enumerate M. tuberculosis
burden were strongly associated.
In summary, this study determined that assaying the RS ratio in sputum is both
repeatable and reproducible. The RS ratio may serve as a novel PD marker that offers a
new physiologic perspective on TB treatment, distinct from existing assays of M. tuber-
culosis burden.
MATERIALS ANDMETHODS
Participant recruitment and specimen collection. Participants were enrolled at Naguru Referral
Hospital in Kampala, Uganda, from August 2018 to March 2019 as a component of a longitudinal obser-
vational cohort study of adults with pneumonia called the International HIV-Associated Opportunistic
Pneumonias-Inflammation, Ageing, Microbes, and Obstructive Lung Disease study (21, 22). Participants
were$18 years of age, with persistent cough, without signs of extrapulmonary TB, and without TB treat-
ment within the past 2 years.
Each participant provided 4 spot sputum samples. The first and second sputum samples were proc-
essed for smear microscopy, liquid and solid cultures, and Xpert, as described in the supplemental mate-
rial. Auramine O fluorescent smear microscopy used the direct method. Drug-susceptible pulmonary TB
was confirmed by sputum smear microscopy, culture, and Xpert (23). Smear microscopy used a small
amount of primary sputum. Culture and Xpert each used 1 ml of processed sputum. Two additional spu-
tum samples were collected within a 1-h time interval for RNA-based assays in a guanidine thiocyanate
(GTC)-based RNA preservative as described in the supplemental material. Both the parent and current
study were approved by the institutional review boards in Uganda and the United States. All participants
provided written informed consent for the use of their sputa and clinical data for a biomarker study.
RNA extraction and quantification of rRNA burden and RS ratio. Total RNA was extracted from
paired sputum samples using standard methods described in the supplemental material. Following
reverse transcription, 16S and 23S rRNA transcripts were quantified in triplicate via reverse transcription
quantitative PCR (RT-qPCR). Absolute copies were determined by reference to a standard DNA ladder.
Employing methods similar to those used for the molecular bacterial load assay (24, 25), we used a
spike-in to adjust for loss in RNA extraction (“retention percentage”) and normalized by sputum weight
to estimate the burden of 16S or 23S rRNA in sputum (supplemental material). For the RS ratio assay,
droplet digital PCR (ddPCR) was used to quantify the abundance of pre-rRNA relative to 23S rRNA, as
previously described (9).
Evaluation of repeatability and reproducibility. To understand the sources of variability in the RS
ratio, we defined repeatability and reproducibility in three ways. Repeatability was the agreement
among three replicate RS ratio results within a single experiment (i.e., technical replicates). Second, inter-
observer reproducibility was the agreement between RS ratio results in the same samples conducted by
two different lab workers using different instruments at a 12-month interval. Finally, we defined a spu-
tum-to-sputum biological reproducibility as the agreement between RS ratio results in two separate
sputa (SS1 and SS2) collected within an hour of each other. We additionally evaluated variability in mea-
surement of M. tuberculosis rRNA burden by qPCR, quantifying repeatability in technical replicates and
sputum-to-sputum biological reproducibility. Repeatability and reproducibility were estimated based on
the intraclass correlation coefficient (ICC), ranging from 0, indicating no agreement, to 1, indicating per-
fect agreement (26). We implemented the one-way random effects ICC framework (27), which assumes
that each participant is measured by a different set of assays, using the function icc in the irr R package.
RS Ratio Reproducibility and Association with Burden

















































Comparison of RS ratio with existing and investigational markers ofM. tuberculosis burden.We
tested the association of the RS ratio with sputum smear grade, TTP, Xpert, and rRNA burden using
Spearman correlation tests. For the burden of 16S and 23S rRNA, we selected the median of triplicates
for statistical analysis. P values of ,0.05 were considered statistically significant. Relationships of the RS
ratio and markers of M. tuberculosis burden with clinical and demographic factors were tested using
two-sample Wilcoxon tests. Statistical analysis was conducted in R v 3.5.3 (R Development Core Team,
Vienna, Austria).
Data availability. All primary data are included in the supplemental material.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
SUPPLEMENTAL FILE 1, PDF file, 0.3 MB.
SUPPLEMENTAL FILE 2, XLSX file, 0.02 MB.
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